162 related articles for article (PubMed ID: 8558198)
21. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
22. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
Bidet A; Dulucq S; Smol T; Marceau-Renaut A; Morisset S; Coiteux V; Noël-Walter MP; Nicolini FE; Tigaud I; Luquet I; Struski S; Gaillard B; Penther D; Tondeur S; Nadal N; Hermet E; Véronèse L; Réa D; Gervais C; Theisen O; Terré C; Cony-Makhoul P; Lefebvre C; Gaillard JB; Radford I; Vervaeke AL; Barin C; Chapiro E; Nguyen-Khac F; Etienne G; Preudhomme C; Mahon FX; Roche-Lestienne C;
Haematologica; 2019 Jun; 104(6):1150-1155. PubMed ID: 30573507
[TBL] [Abstract][Full Text] [Related]
23. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
Maloisel F; Uettwiller F; Laplace A; Lioure B; Herbrecht R; Mark M; Dufour P
Cancer Genet Cytogenet; 1999 Sep; 113(2):172-6. PubMed ID: 10484986
[TBL] [Abstract][Full Text] [Related]
24. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation.
Higano CS; Raskind WH; Singer JW
Blood; 1992 Sep; 80(6):1437-42. PubMed ID: 1520870
[TBL] [Abstract][Full Text] [Related]
25. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
[TBL] [Abstract][Full Text] [Related]
26. [Initial treatment of chronic myelogenous leukemia--interferon or bone marrow transplantation].
Urabe A
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1381-6. PubMed ID: 10500523
[TBL] [Abstract][Full Text] [Related]
27. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Kantarjian HM; O'Brien S; Cortes JE; Smith TL; Rios MB; Shan J; Yang Y; Giles FJ; Thomas DA; Faderl S; Garcia-Manero G; Jeha S; Wierda W; Issa JP; Kornblau SM; Keating M; Resta D; Capdeville R; Talpaz M
Clin Cancer Res; 2002 Jul; 8(7):2167-76. PubMed ID: 12114417
[TBL] [Abstract][Full Text] [Related]
28. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
[TBL] [Abstract][Full Text] [Related]
29. [Philadelphia chromosome-positive chronic myeloid leukemia in the elderly: presenting features, natural history and survival].
Hernández-Boluda JC; Cervantes F; Camós M; Costa D; Rafel M; Montserrat E
Med Clin (Barc); 1999 May; 112(15):565-7. PubMed ID: 10365381
[TBL] [Abstract][Full Text] [Related]
30. [Prognosis of clonal chromosomal abnormalities in Philadelphia negative metaphases cells in chronic myeloid leukemia with tyrosine kinase inhibitor therapy].
Zhao HF; Zhang Y; Hu JY; Li Z; Zhou J; Yu FK; Zu YL; Zhou H; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):209-214. PubMed ID: 30929388
[No Abstract] [Full Text] [Related]
31. A pericentric inv(9)(p22q34) of the der(9)t(9;22)(q34;q11.2) is a recurrent secondary anomaly in Ph-positive leukemia.
Pan J; Xue Y; Qiu H; Chen S; Zhang J; Wu Y; Shen J; Wang Y
Cancer Genet Cytogenet; 2010 Dec; 203(2):333-40. PubMed ID: 21156255
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetic abnormalities in 532 patients with myeloid leukemias and myelodyplastic syndrome. The Czechoslovak MDS Cooperative Group.
Michalová K; Musilová J; Zemanová Z
Czech Med; 1990; 13(4):133-44. PubMed ID: 2081440
[TBL] [Abstract][Full Text] [Related]
33. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia.
Ariyama T; Inazawa J; Uemura Y; Kakazu N; Maekawa T; Urase F; Irimajiri K; Horiuchi A; Nakamura Y; Abe T
Cancer Genet Cytogenet; 1995 May; 81(1):20-3. PubMed ID: 7773954
[TBL] [Abstract][Full Text] [Related]
34. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of chromosome aberrations in childhood acute lymphoid leukemia (ALL).
Balogh E; Oláh E; Kovács I
Acta Paediatr Hung; 1990; 30(2):271-89. PubMed ID: 2248806
[TBL] [Abstract][Full Text] [Related]
36. Karyotype abnormalities and their clinical significance in a group of chronic myeloid leukemia patients treated with hematopoietic stem cell transplantation.
Otero L; Ornellas MH; de Azevedo AM; Tavares Rde C; Pires V; Abdelhay E; Bouzas LF; Fernandez Tde S
Sao Paulo Med J; 2007 Jul; 125(4):246-9. PubMed ID: 17992398
[TBL] [Abstract][Full Text] [Related]
37. [Cytogenetic and clinical features of Philadelphia chromosome positive leukemias].
Becher R; Kloke O
Verh Dtsch Ges Pathol; 1990; 74():36-42. PubMed ID: 1708614
[TBL] [Abstract][Full Text] [Related]
38. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Kantarjian HM; O'Brien S; Cortes JE; Shan J; Giles FJ; Rios MB; Faderl SH; Wierda WG; Ferrajoli A; Verstovsek S; Keating MJ; Freireich EJ; Talpaz M
Cancer; 2003 Feb; 97(4):1033-41. PubMed ID: 12569603
[TBL] [Abstract][Full Text] [Related]
39. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
Mohamed AN; Pemberton P; Zonder J; Schiffer CA
Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
[TBL] [Abstract][Full Text] [Related]
40. [Molecular-cytogenetic monitoring of different regimens of treatment in patients with chronic myeloid leukemia].
Diachenko LV; Zakharova AV; Aseeva EA; Turkina AG; Khoroshko ND; Vodinskaia LA; Udovichenko AI; Domracheva EV
Ter Arkh; 2004; 76(7):41-4. PubMed ID: 15379126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
